NDA 018723 · Abbvie
Depakote
Divalproex Sodium · Oral
Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1983
Mar 10, 1983
Approved uses
3
Original approval plus efficacy supplements
Registered trials
398
85 Phase 3, 16 recruiting
FAERS reports
42,456
28,969 serious, 2,376 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LIFE THREATENING ADVERSE REACTIONS Hepatotoxicity General Population: Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months [see Warnings and Precautions ( 5.1 )]. Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with...
What it is approved for
From the label in effect Mar 31, 2026.
Depakote is an anti-epileptic drug indicated for: Treatment of manic episodes associated with bipolar disorder ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) Prophylaxis of migraine headaches ( 1.3 ) 1.1 Mania Depakote (divalproex sodium) is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. The efficacy of Depakote was established in 3-week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania [see Clinical Studies ( 14.1 ) ] . The safety and effectiveness of Depakote for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use Depakote for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. 1.2 Epilepsy Depakote is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Depakote is also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the...
Mechanism: Divalproex sodium dissociates to the valproate ion in the gastrointestinal tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 20, 1996 Supplement 20 · Efficacy
- Mar 18, 1996 Supplement 17 · Efficacy
- Mar 10, 1983 Original approval · Type 3 - New Dosage Form Other Important Information from FDA
3 products under this application
- DEPAKOTE · DIVALPROEX SODIUM EQ 250MG VALPROIC ACID · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
- DEPAKOTE · DIVALPROEX SODIUM EQ 500MG VALPROIC ACID · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
- DEPAKOTE · DIVALPROEX SODIUM EQ 125MG VALPROIC ACID · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Divalproex" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed EpilepsyPivotal-lookingCompleted
UCB PharmaUCB
NCT00175903 · 1,701 participants · Start Feb 2005 · Primary completion Oct 2007
Drug: Levetiracetam; Carbamazepine Controlled Release (CBZ-CR) and 1 more · For: Epilepsy
Sites: Adelaide, Australia; Bedford Park, Australia; Brisbane, Australia · 229 sites in all
- A Study of Aripiprazole (Abilify) in Patients With Bipolar ManiaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00261443 · 1,270 participants · Start Sep 2005 · Primary completion Jun 2009
Drug: Lithium or Valproate with placebo (PBO); Lithium or Valproate with Aripiprazole · For: Bipolar Disorder
Sites: Tuscaloosa, Alabama; Anaheim, California; Cerritos, California · 83 sites in all
- Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or DivalproexPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01358357 · 965 participants · Start Jun 2011 · Primary completion Apr 2015
Drug: Lurasidone; Placebo · For: Bipolar I Disorder
Sites: Dothan, Alabama; Glendale, California; Los Angeles, California · 105 sites in all
- A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With EpilepsyPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00236717 · 865 participants · Start Sep 1997
Drug: Topiramate; Carbamazepine; Valproate · For: Epilepsy; Seizures
- Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I DisorderPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00081380 · 710 participants · Start Mar 2004
Drug: Seroquel®, quetiapine fumarate (atypical antipsychotic); lithium (mood stabilizer) and 1 more · For: Bipolar Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 94 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,904
- seizure2,439
- weight increased1,994
- off label use1,984
- nausea1,957
- fatigue1,816
- pain1,808
- somnolence1,746
- tremor1,641
- fall1,636
- anxiety1,604
- vomiting1,530
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,146 |
| 2005 | 1,255 |
| 2006 | 1,190 |
| 2007 | 1,179 |
| 2008 | 1,195 |
| 2009 | 2,479 |
| 2010 | 2,155 |
| 2011 | 2,051 |
| 2012 | 2,037 |
| 2013 | 1,750 |
| 2014 | 1,850 |
| 2015 | 2,469 |
| 2016 | 2,641 |
| 2017 | 2,201 |
| 2018 | 2,090 |
| 2019 | 2,126 |
| 2020 | 1,903 |
| 2021 | 1,982 |
| 2022 | 2,044 |
| 2023 | 1,768 |
| 2024 | 1,780 |
| 2025 | 1,858 |
| 2026 | 1,302 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Depakote (Divalproex Sodium)
2024 spending
$11.9M
Beneficiaries
2,352
15,783 claims
Per beneficiary
$5,045
$5.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,805,669 |
| 2021 | $14,495,591 |
| 2022 | $13,496,837 |
| 2023 | $12,924,238 |
| 2024 | $11,865,909 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy of impulse control disorders: A systematic review.
Tahir T, Wong MM, Maaz M, et al. · Psychiatry Res 2022 · Systematic Review
- Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: a systematic review and network meta-analysis of randomized controlled trials.
Huang W, He S, Liu M, et al. · Mol Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · Addiction 2022 · Systematic Review, Network Meta-Analysis
- Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials.
Nestsiarovich A, Gaudiot CES, Baldessarini RJ, et al. · Eur Neuropsychopharmacol 2022 · Meta-Analysis, Research Support, N.I.H., Extramural
- Integrative Systematic Review on Pharmacological, Psychotherapeutic, and Neurostimulatory Treatment Options in Treatment-Resistant Anxiety Disorders.
Schiele MA, Fagan HA, Baldwin DS, et al. · Psychother Psychosom 2026 · Systematic Review, Research Support, Non-U.S. Gov't
- Anticonvulsant drugs for migraine prophylaxis.
Chronicle E, Mulleners W · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.